Analysis of the immunity effects after enhanced hepatitis B vaccination on patients with lymphoma

Zhuang, Wei-Huang; Wang, Yaping

doi:10.1080/10428194.2019.1672053

Cited by 7 publications

(3 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At the same time, inadequate preparation of medical facilities and sanitation facilities and severe cold chain breaks are important factors affecting willingness and vaccination effectiveness. Huang et al, by understanding the positive rate of HBsAb in lymphoma patients after receiving different doses of hepatitis B vaccine, evaluated the immune effect of different doses of Hepatitis B vaccine and analyzed the influencing factors (Zhuang and Wang 2020 ). Lymphoma patients can get a better immune effect if they receive a high-dose hepatitis B vaccine.…”

Section: Introductionmentioning

confidence: 99%

New theoretical ISM-K2 Bayesian network model for evaluating vaccination effectiveness

Xie

Xiong

et al. 2022

J Ambient Intell Human Comput

View full text Add to dashboard Cite

Aiming at the difficulty in obtaining a complete Bayesian network (BN) structure directly through search-scoring algorithms, authors attempted to incorporate expert judgment and historical data to construct an interpretive structural model with an ISM-K2 algorithm for evaluating vaccination effectiveness (VE). By analyzing the influenza vaccine data provided by Hunan Provincial Center for Disease Control and Prevention, risk factors influencing VE in each link in the process of “Transportation—Storage—Distribution—Inoculation” were systematically investigated. Subsequently, an evaluation index system of VE and an ISM-K2 BN model were developed. Findings include: (1) The comprehensive quality of the staff handling vaccines has a significant impact on VE; (2) Predictive inference and diagnostic reasoning through the ISM-K2 BN model are stable, effective, and highly interpretable, and consequently, the post-production supervision of vaccines is enhanced. The study provides a theoretical basis for evaluating VE and a scientific tool for tracking the responsibility of adverse events of ineffective vaccines, which has the value of promotion in improving VE and reducing the transmission rate of infectious diseases.

show abstract

Section: Introductionmentioning

confidence: 99%

New theoretical ISM-K2 Bayesian network model for evaluating vaccination effectiveness

Xie

Xiong

et al. 2022

J Ambient Intell Human Comput

View full text Add to dashboard Cite

show abstract

“…Mannose-modified nanoparticles can effectively avoid the clearance and decomposition of nanoparticles caused by immune responses, thus extending their circulation time in the body and increasing their accumulation in tumor tissues [160]. Additionally, changing the mannose can improve the specific binding between nanoparticles and tumor cells, allowing for more precise targeted delivery and a better immune response against the tumor in the vaccine [161][162][163][164][165].…”

Section: Stability and Biocompatibility Of Nanoparticlesmentioning

confidence: 99%

A Mannose-Modified Lipid Calcium Phosphate Nanoparticle Vaccine Increased the Anti-Tumor Immune Response by Modulating the Tumor Microenvironment

Wu,

Qian,

et al. 2024

Preprint

View full text Add to dashboard Cite

With the rapid development of tumor immunotherapy, nanoparticle vaccines have attracted much attention as a potential therapeutic strategy. The potential role of the mannose-modified lipid calcium phosphate nanoparticle vaccine in enhancing the anti-tumor immune response was investigated. The aim of this study was to investigate the effect of mannose modification on the immune response of nanoparticles in regulating the tumor microenvironment through systematic review and analysis and to explore its potential clinical application in tumor therapy. Currently, despite the potential advantages of nanoparticle vaccines in immunotherapy, achieving an effective immune response in the tumor microenvironment remains a challenge. Tumor immune escape and overexpression of immunosuppressive factors limit its clinical application. Therefore, this study will explore how to intervene in the immunosuppressive mechanism in the tumor microenvironment through mannose-modified lipid calcium phosphate nanoparticle vaccines so as to improve the immunotherapy effect of tumor patients and provide new ideas and strategies for the field of tumor therapy.

show abstract

“…Both groups of patients show insufficient serological response to both bacterial (pneumococcal) and viral (hepatitis B, influenza) vaccines. [4][5][6][7][8][9] In this study, both serological and cell-mediated immune response to SARS-CoV-2 mRNA vaccines 10,11 in patients treated with B-cell-targeting therapy was investigated. Based on previous research, we anticipated the impairment of serological response to vaccinations.…”

Section: Introductionmentioning

confidence: 99%

Cellular and Humoral Immune Response to SARS-CoV-2 mRNA Vaccines in Patients Treated with either Ibrutinib or Rituximab

Bacova¹,

Kohutova²,

Zubata³

et al. 2021

Preprint

View full text Add to dashboard Cite

Patients treated with B-cell targeting therapies like Rituximab or Ibrutinib have decreased serological response to various vaccines. In this study, we tested serological and cellular response to SARS-CoV-2 mRNA vaccines in 16 patients treated with Ibrutinib, 16 treated with maintenance Rituximab, 18 patients with chronic lymphocytic leukaemia (CLL) with watch and wait status and 21 healthy volunteers. In comparison to the healthy volunteers, where serological response was achieved by 100% subjects, patients on B-cell-targeting therapy (Ibrutinib and Rituximab) had their response dramatically impaired. The serological response was achieved in 0% of Rituximab treated, 18% of Ibrutinib treated and 50% of untreated CLL patients. Cell-mediated immunity analysed by the whole blood Interferon-γ Release immune Assay developed in 80% of healthy controls, 62% of Rituximab treated, 75% of Ibrutinib treated and 55% of untreated CLL patients. The probability of cell-mediated immune response development negatively correlates with disease burden mainly in CLL patients. Our study shows that even though the serological response to SARS-CoV-2 vaccine is severely impaired in patients treated with B-cell-targeting therapy, the majority of these patients develop sufficient cell-mediated immunity. The vaccination of these patients therefore might be meaningful in terms of protection against SARS-CoV-2 infection.

show abstract

Analysis of the immunity effects after enhanced hepatitis B vaccination on patients with lymphoma

Cited by 7 publications

References 20 publications

New theoretical ISM-K2 Bayesian network model for evaluating vaccination effectiveness

New theoretical ISM-K2 Bayesian network model for evaluating vaccination effectiveness

A Mannose-Modified Lipid Calcium Phosphate Nanoparticle Vaccine Increased the Anti-Tumor Immune Response by Modulating the Tumor Microenvironment

Cellular and Humoral Immune Response to SARS-CoV-2 mRNA Vaccines in Patients Treated with either Ibrutinib or Rituximab

Contact Info

Product

Resources

About